Home Autophagy Ferroptosis inhibitor - Autophagy activator - HIF activator - Beta Amyloid inhibitor Deferoxamine mesylate For research use only.

Deferoxamine mesylate

Synonyms: Ba 33112, Desferrioxamine B, DFOM, NSC 644468, DFO

Deferoxamine mesylate is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent. Deferoxamine is a ferroptosis inhibitor that stabilizes HIF-1α expression and improves HIF-1α transactivity in hypoxic and hyperglycemic states in vitro. Deferoxamine decreases beta-amyloid (Aβ) deposition and induces autophagy.Please do not prepare stock solutions with normal saline or PBS, as precipitation may occur.

Deferoxamine mesylate Chemical Structure

Deferoxamine mesylate Chemical Structure

CAS: 138-14-7

Selleck's Deferoxamine mesylate has been cited by 78 publications

Purity & Quality Control

Batch: Purity: 99.74%
99.74

Products often used together with Deferoxamine mesylate

Z-VAD-FMK

Deferoxamine mesylate can reverse the cell proliferative activity of granulosa cells in EMFF but not Z-VAD-FMK.

Ni Z, et al. Cell Death Dis. 2022 Jul 4;13(7):579.

Fer-1 (Ferrostatin-1)

Deferoxamine mesylate and Ferrostatin-1 can reverse the cell proliferative activity of granulosa cells in EMFF.

Ni Z, et al. Cell Death Dis. 2022 Jul 4;13(7):579.

SRS11-92

Deferoxamine mesylate can reverse the cell proliferative activity of granulosa cells in EMFF but not Necrostatin-1.

Ni Z, et al. Cell Death Dis. 2022 Jul 4;13(7):579.

Rosiglitazone

Deferoxamine mesylate and Rosiglitazone are inhibitors of ferroptosis and induce autophagy.

Deferoxamine mesylate Related Products

Choose Selective Ferroptosis Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 4.51 μM. 17602603
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 5 μM. 19601577
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 7.35 μM. 19216562
A549 Antiproliferative assay 72 hrs Antiproliferative activity at human A549 cells after 72 hrs by MTT assay, IC50 = 7.5 μM. 22861499
SK-N-MC Antiproliferative assay 96 hrs Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay, IC50 = 8.58 μM. 17064069
MDCK Toxicity assay Toxicity in MDCK cells by MTT method, IC50 = 9.49 μM. 20041672
SK-N-MC Cytotoxicity assay 72 hrs Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 9.89 μM. 20303768
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 10 μM. 22861499
DMS53 Antiproliferative assay 72 hrs Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay, IC50 = 10 μM. 22861499
SK-MN-C Antiproliferative assay Antiproliferative activity against human SK-MN-C cells by MTT assay, IC50 = 12.05 μM. 18159922
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 12.5 μM. 22858101
SK-N-MC Antiproliferative assay Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50 = 14.22 μM. 17963372
SK-N-MC Toxicity assay Toxicity in human SK-N-MC cells by MTT method, IC50 = 16.04 μM. 20041672
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 16.81 μM. 28841514
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM. 21055950
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM. 22172311
U2OS Function assay 30 mins Activation of human HIF1alpha expressed in DFX-induced human U2OS cells incubated for 30 mins prior to DFX-induction measured after overnight incubation by luciferase reporter gene assay, EC50 = 17.8 μM. 22172704
HL60 Cytotoxicity assay Cytotoxicity against human HL60 cells by alamar blue assay, GI50 = 18.4 μM. 23266185
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells measured after 72 hrs at 37 degC by MTT assay, IC50 = 21.63 μM. 23312948
SK-N-MC Antiproliferative assay Antiproliferative activity against human SK-N-MC cells, IC50 = 22 μM. 19601577
SK-N-MC Antiproliferative assay 72 hrs Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay, IC50 = 22.7 μM. 21846118
SK-N-MC Cytotoxicity assay 72 hrs Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 22.7 μM. 23276209
K562 Cytotoxicity assay Cytotoxicity against human K562 cells, GI50 = 33.1 μM. 23266185
HT29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT29 cells after 72 hrs by MTS assay, IC50 = 36.1 μM. 18345610
HT-29 Cell cycle assay 10 uM 24 hrs Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 10 uM after 24 hrs 20353152
HT-29 Cell cycle assay 5 uM 24 hrs Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 5 uM after 24 hrs 20353152
HCT116 Function assay 24 hrs Photocytotoxicity against human HCT116 cells expressing wild type p53 incubated for 24 hrs followed by light irradiation measured after 24 hrs by MTS assay in presence of ALA and FeCl3 24900837
HeLa Bacteriostatic assay >100 uM 1 hr Bacteriostatic activity against Chlamydia trachomatis serovar L2 infected in human HeLa cells assessed as growth inhibition compound treated at >100 uM for 1 hr prior infection measured 24 hrs post infection by microscopy 25027937
SK-N-BE(2)-M17 Cytoprotection assay 1 mM 2 hrs Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by LDH assay 28285915
SK-N-BE(2)-M17 Cytoprotection assay 1 mM 2 hrs Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by LDH assay 28285915
SK-N-BE(2)-M17 Cytoprotection assay 1 mM 2 hrs Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by MTT assay 28285915
SK-N-BE(2)-M17 Cytoprotection assay 1 mM 2 hrs Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by MTT assay 28285915
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
Click to View More Cell Line Experimental Data

Biological Activity

Description Deferoxamine mesylate is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent. Deferoxamine is a ferroptosis inhibitor that stabilizes HIF-1α expression and improves HIF-1α transactivity in hypoxic and hyperglycemic states in vitro. Deferoxamine decreases beta-amyloid (Aβ) deposition and induces autophagy.Please do not prepare stock solutions with normal saline or PBS, as precipitation may occur.
Targets
HIF-1α [1] Beta Amyloid [1] Ferroptosis [2]
In vitro
In vitro

Deferoxamine mesylate, the iron chelator and ferroptosis inhibitor, rescues neutrophil death induced by systemic lupus erythematosus (SLE) serum, suggesting that ferroptosis may be the main form of neutrophil death in SLE.[3]
Cell Research Cell lines Healthy neutrophil cell
Concentrations 1/10/100 μM
Incubation Time 16 h
Method

Cells are cultured in complete RPMI 1640 basic medium (Gibco) with 100 U/ml penicillin, 100 μg/ml streptomycin and 20% serum from ten randomly selected patients with SLE or age- and sex-matched healthy controls (HCs), and incubated at 37 ℃ in a humidified atmosphere of 20% O2 and 5% CO2. HC neutrophil cell viability treated with two ferroptosis inhibitors, LPX-1 (10/100/1,000 nM) or DFO (1/10/100 μM), two necroptosis inhibitors, Nec-1 (10/100/1,000 nM) or NSA (10/100/1,000 nM), or apoptosis inhibitor Z-VAD (0.1/1/10 μM) for 16 h are assessed by flow cytometry.
In Vivo
In vivo

Deferoxamine mesylate (Ba 33112, Desferrioxamine B, DFOM, NSC 644468) is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent.
Animal Research Animal Models Mongrel dogs
Dosages 25 mg/kg
Administration i.m.

Chemical Information & Solubility

Molecular Weight 656.79 Formula

C26H52N6O11S
CAS No. 138-14-7 SDF --
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 100 mg/mL ( (152.25 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 100 mg/mL

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Deferoxamine mesylate | Deferoxamine mesylate supplier | purchase Deferoxamine mesylate | Deferoxamine mesylate cost | Deferoxamine mesylate manufacturer | order Deferoxamine mesylate | Deferoxamine mesylate distributor